Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.35 |
| ▸ | RELA | Q04206 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TOP1 | P11387 | 2/20 | 0.33 |
| ▸ | HRAS | P01112 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6527019 | 0.86 | POLB (0.34) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL8889890 | 0.80 | TDP1 (0.41) | TDP1NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL3357113 | 0.78 | HSD17B10 (0.44) | TDP1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL14441973 | 0.78 | CYP2C9 (0.43) | TDP1POLBMEN1KMT2ACYP2C9 | |
| SCHEMBL26377893 | 0.76 | TOP1 (0.44) | TDP1POLBMEN1KMT2ACYP2C9 | |
| SCHEMBL7541678 | 0.76 | HRAS (0.53) | PKMPOLBTOP1HRASESR1 | |
| SCHEMBL7127221 | 0.75 | HRAS (0.57) | POLBTOP1HRASESR1ESR2 | |
| SCHEMBL7119707 | 0.75 | HRAS (0.57) | POLBTOP1HRASESR1ESR2 | |
| SCHEMBL14535121 | 0.74 | TOP1 (0.45) | TDP1POLBTOP1HRASESR1 | |
| SCHEMBL3459108 | 0.74 | HRAS (0.51) | POLBTOP1HRASESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6753316-B1 | 3-ACRYLAMIDOPYRAZOLE-5-CARBOXAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 2004-06-22 | — | — | US | disclosed |
| CN-1116281-C | Acryloyl substituted distamycin derivatives, process for their preparation, and their use as antitumor and antiviral agents | PHARMACIA & UPJOHN SPA (IT) | 2003-07-30 | — | — | CN | disclosed |
| US-20030023031-A1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | PHARMACIA & UPJOHN S.P.A. | 2003-01-30 | — | — | US | disclosed |
| EP-0722446-B1 | DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS | PHARMACIA ITALIA SPA (IT) | 2002-12-11 | — | — | EP | disclosed |
| US-6482920-B1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | PHARMACIA ITALIA, S.P.A. (IT) | 2002-11-19 | — | — | US | disclosed |
| EP-0915845-B1 | ACRYLOYL SUBSTITUTED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AND ANTIVIRAL AGENTS | PHARMACIA & UPJOHN SPA (IT) | 2001-09-12 | — | — | EP | disclosed |
| CN-1226232-A | Acryloyl substituted distamycin derivatives, process for their preparation, and their use as antitumor and antiviral agents | PHARMACIA & UPJOHN SPA (IT) | 1999-08-18 | — | — | CN | disclosed |
| US-5753629-A | AMINO ACID DERIVATIVE ANTIBIOTICS; VIRICIDES | PHARMACIA S.P.A. (IT) | 1998-05-19 | — | — | US | disclosed |
| CN-1131946-A | Distamycin A analogues as antitumour or antiviral agents | PHARMACIA SPA (IT) | 1996-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023031-A1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | EIF2AK2, ACR, EIF4A1 | TDP1 2891/4885NPC1 19/4885RAB9A 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.